During last month’s European Society for Medical Oncology Asia 2018 annual meeting, held in Singapore from November 23 to November 25, researchers presented data demonstrating the biosimilarity of QL1101 with reference bevacizumab (Avastin).
During last month’s European Society for Medical Oncology’s Asia 2018 annual meeting, held in Singapore from November 23 to November 25, researchers presented data demonstrating the biosimilarity of QL1101 with reference bevacizumab (Avastin).
QL1101 is a biosimilar product being developed by Chinese drug developer Qilu Pharmaceutical, which funded the phase 3 clinical trial that enrolled 532 patients with nonsquamous non—small-cell lung cancer (NSCLC). The objective of the study was to evaluate the effectiveness of the proposed biosimilar versus the reference bevacizumab.
The patients were randomized to receive either the proposed biosimilar (n = 266) or the reference product (n = 266), and both groups received their therapy in combination with paclitaxel and carboplatin every 3 weeks as a single treatment for 6 cycles. After the 6 cycles were completed, both groups received QL1101 as monotherapy maintenance treatment until disease progression, intolerable toxicity, initiation of a different treatment, loss to follow-up, or death. The primary end point was the best objective response rate (ORR) evaluated by the blind independent imaging review committee at week 18.
At week 18, the ORR of the biosimilar group was 52.26%, with 0 patients achieving a complete response (CR) and 139 patients achieving a partial response (PR). The ORR in the reference group was 56.02%, with 1 patient achieving CR, and 148 achieving PR. The risk ratio value was 0.917 (90% CI, 0.807-1.043), which fell within the prespecified equivalence margin of 0.75 to 1.33.
The researchers reported that the incidences of treatment-related adverse events (AEs) and immunogenicity were similar between the 2 treatment groups, and that no neutralizing antibodies to bevacizumab were detected. No unexpected serious AEs were observed.
The authors concluded that QL1101 and its reference are equivalent in clinical efficacy in nonsquamous NSCLC and that the safety profiles of the 2 drugs are similar.
Reference
Han B, Li K, Chu T, et al. A multi-center, randomized, double-blind, parallel, two-group phase iii trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer. Presented at: European Society for Medical Oncology Asia 2018 Congress; November 23-25, 2018; Singapore. Abstract 396O. cslide.ctimeetingtech.com/asia2018/attendee/confcal/session/calendar?q=biosimilar.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.